These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36531834)

  • 1. Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study.
    Xie Y; Zhu H; Guo Y; Ma Z; Qi X; Yang F; Mao R; Zhang J
    Can J Gastroenterol Hepatol; 2022; 2022():4325352. PubMed ID: 36531834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs.
    Huang J; Zhang K; Chen W; Liao J; Luo X; Chen R
    Sci Rep; 2017 Oct; 7(1):13383. PubMed ID: 29042662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genetic variant of
    Luo M; Dong C; Liang X; Na R; Zhou B; Hou J; Jiang D-K
    J Clin Microbiol; 2024 Feb; 62(2):e0139623. PubMed ID: 38259071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
    Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
    [No Abstract]   [Full Text] [Related]  

  • 9. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients.
    Chu JH; Huang Y; Xie DY; Deng H; Wei J; Guan YJ; Li GJ; Zeng YL; Yang JH; Chen XY; Shang J; Li JB; Gao N; Gao ZL
    J Viral Hepat; 2022 Sep; 29(9):765-776. PubMed ID: 35718996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL13 variant predicts pegylated-interferon α treatment response in HBeAg-positive chronic hepatitis B patients.
    Luo M; Zhang L; Yang C; Zhou B; Hou J; Jiang DK
    J Med Virol; 2023 Jul; 95(7):e28963. PubMed ID: 37470204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher BST2 Expression Promotes the Anti-HBV Effect of IFN-α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg-Positive Chronic Hepatitis B Patients.
    Chen J; Hou J; Na R; Zhou B; Hou J; Jiang DK
    Clin Pharmacol Ther; 2024 Feb; 115(2):361-370. PubMed ID: 38018367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.
    Wei W; Wu Q; Zhou J; Kong Y; You H
    Int J Environ Res Public Health; 2015 Aug; 12(8):10039-55. PubMed ID: 26308024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure.
    Weng M; Zeng WZ; Wu XL; Zhang Y; Jiang MD; Wang Z; Zhou DJ; He X
    Virol J; 2013 Sep; 10():277. PubMed ID: 24010768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A study of the clinical curative effect of nucleos(t)ide analogues treated to pegylated interferon-α add-on therapy in patients with chronic hepatitis B].
    Liang H; Wang C; Zhu PF; Zeng QL; Huang XB; Pan YF; Pan YJ; Hu QY; Luo X; Chen H; Yu ZJ; Lu FM; Lyu J
    Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1297-1305. PubMed ID: 38253074
    [No Abstract]   [Full Text] [Related]  

  • 18. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
    Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
    Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B.
    Li H; Wang H; Peng C; Zheng X; Liu J; Weng ZH; Yang DL
    J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):547-555. PubMed ID: 28786051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.